A Phase I Study of FT819 in Subjects With B-cell Malignancies

Study Summary

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Interventions

Study Locations

Facility	City	State	Country
University of Alabama at Birmingham	Birmingham	Alabama	United States
Mayo Arizona	Phoenix	Arizona	United States
UC Davis	Davis	California	United States
Scripps Green Hospital	La Jolla	California	United States
UCLA Ronald Reagan Medical Center	Los Angeles	California	United States
Stanford Cancer Institute	Palo Alto	California	United States
University of Florida	Gainesville	Florida	United States
Mayo Florida	Jacksonville	Florida	United States
University of Iowa	Iowa City	Iowa	United States
The University of Kansas Cancer Center	Westwood	Kansas	United States
Norton Cancer Institute, St. Matthews Campus	Louisville	Kentucky	United States
Mayo Minnesota	Rochester	Minnesota	United States
University of Nebraska Medical Center	Omaha	Nebraska	United States
Hackensack University Medical Center	Hackensack	New Jersey	United States
Memorial Sloan Kettering Cancer Center	New York	New York	United States
Oregon Health & Sciences University	Portland	Oregon	United States
MD Anderson Cancer Center	Houston	Texas	United States
University of Wisconsin-Madison	Madison	Wisconsin	United States

Official Trial Information

View on ClinicalTrials.gov